Neurotech International Ltd
Company Profile
Business description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), along with Rett Syndrome.
Contact
55 Collins Street
Suite 102, Level 1
MelbourneVIC3000
AUST: +61 394983132
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
18
Stocks News & Analysis
stocks
3 charts on Anthropic’s historic IPO filing
stocks
Weight loss drugs not an existential threat to undervalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,971.40 | 2.60 | 0.03% |
| CAC 40 | 7,886.96 | 0.18 | -0.00% |
| DAX 40 | 25,697.45 | 106.68 | 0.42% |
| Dow JONES (US) | 52,623.43 | 245.86 | 0.47% |
| FTSE 100 | 10,694.50 | 7.96 | 0.07% |
| HKSE | 23,094.83 | 53.51 | 0.23% |
| NASDAQ | 26,521.29 | 43.48 | 0.16% |
| Nikkei 225 | 63,954.19 | 685.82 | 1.08% |
| NZX 50 Index | 13,691.33 | 11.06 | 0.08% |
| S&P 500 | 7,750.34 | 27.74 | 0.36% |
| S&P/ASX 200 | 8,847.30 | 2.80 | -0.03% |
| SSE Composite Index | 3,681.47 | 33.17 | 0.91% |